Natalizumab

Drug Profile

Natalizumab

Alternative Names: AN 10022; AN 100226; Antegren; Anti-alpha4 integrin monoclonal antibody; BG-00002; BG-0002; BG-0002-E; Tysabri

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Elan Corporation
  • Developer Biogen; Biogen Idec; Elan Corporation; Perrigo
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Crohn's disease; Multiple sclerosis
  • Phase II Graft-versus-host disease; Stroke
  • Discontinued Multiple myeloma; Rheumatoid arthritis

Most Recent Events

  • 27 Feb 2017 Perrigo signed a definitive agreement to divest the royalty payments based on global sales of natalizumab to Royalty Pharma
  • 31 May 2016 The Committee of Medicinal Products for Human Use of the European Medicines Agency recommends approval of a variation to the marketing authorization of natalizumab for Multiple sclerosis (relapsing-remitting with inadequate response to any prior therapy) in European Union
  • 18 Apr 2016 The European Commission grants unlimited validity for natalizumab marketing authorization for Multiple sclerosis in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top